Arrowhead Hits the Mark

From a failing company to a record high, Arrowhead Pharmaceuticals Inc. is back and better than ever.

As of Nov. 21, 2019, Arrowhead stock is trading at a record high of $49 a share. It has a new slate of drugs that use slightly different molecular technology to silence disease-causing genes and is targeting a range of different diseases. Read more...